Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP31969
- Development stage
- Phase 2
- Lead developer
- Acesion Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AP31969 is a second-generation, oral small molecule inhibitor of small-conductance calcium-activated potassium (SK) channels, developed by Acesion Pharma for the chronic maintenance treatment of atrial fibrillation (AF). It is designed to prevent AF recurrence by selectively inhibiting SK channels in the atria, thereby reducing proarrhythmia risk—a major limitation of existing antiarrhythmic drugs. Preclinical studies have shown AP31969 has a favorable cardiac safety profile with no QT interval prolongation and low risk of drug-drug interactions. The drug demonstrates good oral pharmacokinetics across animal models and pronounced antiarrhythmic effects in the atria while sparing ventricular tissue. As of 2024, AP31969 is undergoing Phase 1 clinical trials for AF[1][4][5][7].
- Other names
- ap-31969ap31969ap 31969
02
Targets
SK channel (Small-conductance calcium-activated potassium channel)
Beyond the preview
Go deeper on AP31969.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP31969.